Drug Profile

exoSTING

Alternative Names: CDK 002

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Codiak BioSciences
Class Antineoplastics; Exosome therapies; Immunotherapies; Small molecules
Mechanism of Action STING1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours
No development reported Meningeal carcinomatosis
Discontinued Glioblastoma

Most Recent Events

28 Aug 2024 No recent reports of development identified for preclinical development in Meningeal-carcinomatosis in USA (Intrathecal)
23 Dec 2022 Codiak BioSciences completes a phase I/II trial in advanced Solid Tumor in the USA and United kingdom (NCT04592484)
11 Aug 2022 9364946- KDM, FET updated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com